Proteomics International Laboratories (ASX: PIQ) has secured Canadian patent protection for PromarkerEso, its first-in-class blood test for the early detection of esophageal adenocarcinoma.
The granted patent (Canadian Patent No. 2967869), titled "Glycoprotein Biomarkers for Esophageal Adenocarcinoma and Barrett's Esophagus and Uses Thereof," protects the company's proprietary technology in Canada until Nov. 17, 20235 and supports its commercialisation strategy in North America, including direct sales, licensing, and partnership opportunities.
PromarkerEso is designed to detect EAC in its early stages, a critical need given that up to 90% of cases are currently diagnosed late, with a median survival of less than one year.
EAC is strongly associated with chronic acid reflux, which affects an estimated 20% of the US population.
Existing screening relies on invasive endoscopy, which is costly and uncomfortable, leaving many cases undetected.
Clinical studies have demonstrated high accuracy for PromarkerEso, which measures four key serum glycoproteins—alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9, and plasma kallikrein—alongside patient clinical factors such as age, sex, and BMI.
Results are presented as a simple 'traffic light' risk score, guiding high-risk individuals to consult a gastroenterologist.